Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 2a study of SCI-110 for agitation in Alzheimer's disease
MOH_2022-07-10_010529Phase 2Recruiting
- Sponsor
- ד"ר אלכסנדר קפלן
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dronabinol + palmitoylethanolamide, dronabinol and palmitoylethanolamide in Alzheimer's disease (AD), sponsored by ד"ר אלכסנדר קפלן. Started Jun 2021; status: recruiting.
02
Drugs
dronabinol + palmitoylethanolamidedronabinolpalmitoylethanolamide
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on MOH_2022-07-10_010529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-07-10_010529.